Apricus Biosciences (APRI) Appoints Sequenom (SQNM) CFO Maier to Board
Tweet
Share
E-mailGet Alerts APRI Hot Sheet
Join SI Premium – FREE
Apricus Biosciences, Inc. (Nasdaq: APRI) announced that Paul V. Maier, Chief Financial Officer of Sequenom, Inc. (Nasdaq: SQNM) has been appointed to the Company's Board of Directors, effective June 1, 2012.
Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. from 1992 until 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, he spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier received his M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.
Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. from 1992 until 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, he spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier received his M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GoPro promotes CFO Brian Tratt to senior vice president role
- Xylem names Andrea van der Berg as CFO, effective Sept. 2026
- BAE Systems names Michael Loeffler as VP of supply chain
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
